Is Eagle Materials (EXP) Pricing Look Attractive After Recent 3.8% Share Price Pullback

  • If you are wondering whether Eagle Materials at about US$212.72 is offering good value or asking too much, the answer depends on which valuation lens you use.
  • The stock is roughly flat so far this year, with a 0.6% year to date return, after a 6.7% return over the past year and a recent 7 day period where the share price declined 3.8%.
  • Recent coverage around US construction activity and materials demand has kept investors focused on companies like Eagle Materials, as they try to gauge how resilient volumes and pricing could be. At the same time, commentary on input costs and project pipelines has added extra context for how investors assess risk around the current share price.
  • Simply Wall St currently assigns Eagle Materials a valuation score of 4 out of 6, based on checks of where the stock screens as undervalued. Next, you will see how traditional methods like P/E, P/B and discounted cash flow compare, along with a different way of thinking about valuation that may give you a fuller picture by the end of the article.

Find out why Eagle Materials's 6.7% return over the last year is lagging behind its peers.

Advertisement

Approach 1: Eagle Materials Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a stock could be worth by projecting future cash flows and then discounting them back to today, using a required return as the discount rate.

For Eagle Materials, the model uses a 2 Stage Free Cash Flow to Equity approach, anchored on last twelve months free cash flow of about $366.6 million. Analysts provide specific free cash flow projections out to 2029, including $540 million in 2029, and Simply Wall St then extrapolates estimates out to 2035 using these inputs.

Bringing all those projected cash flows back to today and adding them up gives an estimated intrinsic value of about $394.25 per share under this DCF approach. Compared with the recent share price of about $212.72, the model implies the stock trades at a 46.0% discount to this intrinsic value, which indicates that Eagle Materials appears undervalued on this specific cash flow lens.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Eagle Materials is undervalued by 46.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

EXP Discounted Cash Flow as at Jun 2026
EXP Discounted Cash Flow as at Jun 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Eagle Materials.

Approach 2: Eagle Materials Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much you are paying for each dollar of current earnings, which makes it a simple cross check against more complex models like a DCF.

What counts as a “normal” P/E depends on how the market views a company’s growth prospects and risk. Higher growth or lower perceived risk can support a higher P/E, while slower growth or higher risk often lines up with a lower P/E.

Eagle Materials currently trades on a P/E of about 15.53x. That is close to the wider Basic Materials industry average of 15.35x and below the peer group average of 25.76x, so the stock sits toward the lower end of that peer range.

Simply Wall St’s Fair Ratio for Eagle Materials is 17.76x. This is a proprietary estimate of what a reasonable P/E could be, given factors such as the company’s earnings growth profile, profit margins, industry, market cap and key risks. Because it adjusts for these company specific drivers, it can be more informative than a plain comparison with industry or peer averages.

Comparing the Fair Ratio of 17.76x with the current P/E of 15.53x suggests Eagle Materials screens as undervalued on this earnings multiple check.

Result: UNDERVALUED

NYSE:EXP P/E Ratio as at Jun 2026
NYSE:EXP P/E Ratio as at Jun 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Eagle Materials Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are introduced here as a simple story you build around Eagle Materials. This connects your assumptions for future revenue, earnings and margins to a fair value estimate, helps you compare that fair value with the current price to decide whether the stock looks attractive or not, and then automatically refreshes when new information such as earnings or news is added on Simply Wall St’s Community page. This is why different investors can look at the same data and still arrive at very different views, such as a fair value closer to the most optimistic analyst target of about US$246, or nearer the cautious end around US$200.

Do you think there's more to the story for Eagle Materials? Head over to our Community to see what others are saying!

NYSE:EXP 1-Year Stock Price Chart
NYSE:EXP 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Valuation is complex, but we're here to simplify it.

Discover if Eagle Materials might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NYSE:EXP

Eagle Materials

Through its subsidiaries, manufactures and sells heavy construction products and light building materials in the United States.

Good value with mediocre balance sheet.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
67 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
71 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0